UNSPSC 51391749: Eformoterol or formoterol

This classification denotes a beta-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ZZ84GCW8B. European Medicines Agency schedules Formoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07788MIG. Formoterol generally arises in the molecular formula C19H24N2O4.

The term FORMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21.) FORMOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Eformoterol or formoterol bears US NLM identifiers UMLS ID C0060657 and NCI Concept Code C65754. SMILES: OC(CNC(CC1CCC(OC)CC1)C)C1CC(NC=O)C(O)CC1.

UNSPSC 51391749 Eformoterol or formoterol is a Commodity code for pharmaceutical inhalant bronchodilators, but the recent state and local procurement activity recorded under it does not align with this scope. The single recent opportunity tagged to this code—Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026—solicits naloxone and drug deactivation systems, which fall outside the formoterol/eformoterol product family. This mismatch suggests either a data-entry error in the opportunity classification or a jurisdictional tagging anomaly rather than genuine formoterol procurement demand at the state and local level under this code.

The Seminole County opportunity targets 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and a response deadline of July 26, 2023. The contract carries a two-year initial term plus one optional year, mandatory E-Verify compliance, drug-free workplace certification, and workers' compensation and commercial general liability insurance requirements. No standout repeat buyers or geographic concentration emerges from the recent-opportunities block. The code shows minimal relevant recent activity; pursuit should depend on whether your firm supplies naloxone or drug deactivation systems rather than formoterol products, and whether the 2023 close date represents archived rather than live opportunity data.